Accession Number: | 0001610717-23-000073 |
Date: | 2023-05-23 |
Issuer: | 4D MOLECULAR THERAPEUTICS, INC. (FMDT) |
Original Submission Date: |
MILLIGAN JOHN F
C/O 4D MOLECULAR THERAPEUTICS, INC.
5858 HORTON STREET #455
EMERYVILLE, CA 94608
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 17.98 | 2023-05-23 | deemed execution date | A | 33,750 (a) | 2033-05-22 | common stock 33,750 | $17.98 | 33,750 | direct |
ID | footnote |
---|---|
f1 | automatically granted pursuant to the terms of the company's non-employee director compensation program. |
f2 | the stock option vests and becomes exercisable with respect to 1/3 of the total shares on may 23, 2024 and in equal monthly installments thereafter, subject to the reporting person continuing service to issuer through each vesting date, until the shares are fully vested on may 23, 2026. additionally, the stock options will vest in full upon the consummation of a change in control (as defined in the 2020 incentive award plan). |